ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese zucker rats

Obesity

Volumn 16, Issue 4, 2008, Pages 770-776

  Toblli, Jorge E ^a   Mũoz, Marina C ^a   Cao, Gabriel ^a   Mella, José ^b   Pereyra, Lisandro ^b   Mastai, Ricardo ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL ALEMÁN   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; RATTUS;

EID: 41549156590     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2007.114     Document Type: Article

References (36)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
2. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-152.
3. Bataller R, Brenner DA. Liver fibrosis. Clin Invest 2005;115:209-218.
4. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114:842-845.
5. Toblli JE, Ferder L, Angerosa I, Stella, M, Inserra F. Enalapril prevents fatty liver In nephrotic rats. J Nephrol 2002;15:358-367.
6. Bataller R, Sancho-Bru P, Gines P, Brenner DA. Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid Redox Signal 2005:7:1346-1355.
7. Yokohama S, Yoneda M, Haneda M et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004;40:1222-1225.
8. Sun Y, Zhang J, Zhang JQ, Ramires FJ. Local angiotensin II and transforming growth factor-betal in renal fibrosis of rats. Hypertension 2000;35:1078-1084.
9. Yoshiji H, Kuriyama S, Yoshii J et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001;34:745-750.
10. Toblli JE, DeRosa G, Rivas C et al. Cardiovascular protective role of a low-dose antihypertensive combination In obese Zucker rats. J Hypertens 2003;21:611-620.
11. Muñoz MC, Argentino DP, Dominici FP, Turyn D, Toblli JE. Irbesartan restores the in-vivo insulin signaling pathway leading to Akt activation in obese Zucker rats. J Hypertens 2006;24:1607-1617.
12. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001;38:884-890.
13. Toblli JE, Stella I, Mazza ON, Ferder L, Inserra F. The effect of different antihypertensive drugs on cavernous tissue in experimental chronic renal insufficiency. J Nephrol 2006;19:419-428.
14. Toblli JE, DeRosa G, Cao G, Piorno P, Pagano P. ACE inhibitor and angiotensin type I receptor antagonist In combination reduce renal damage In obese Zucker rats. Kidney Int 2004;65:2343-2359.
15. Toblli JE, Cao G, Rivas C, DeRosa G, Domecq P. Angiotensin-Converting enzyme inhibition reduces lipid deposits In myocardium and improves left ventricular function of obese zucker rats. Obesity 2006;14:1586-1595.
16. Rodriguez-Iturbe B, Quiroz Y, Ferrebuz A, Parra G, Vaziri ND. Evolution of renal interstitial Inflammation and NFkB activation In Spontaneously Hypertensive Rats. Am J Nephrol 2004;24:587-594.
17. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-580.
18. Toblli JE, Cao G, DeRosa G, Forcada P. Reduced cardiac expression of plasminogen activator inhibitor 1 and transforming growth factor beta1 in obese Zucker rats by Perindopril. Heart 2005;91:80-86.
19. Yang L, Bataller R, Dulyx J et al.Attenuated hepatic inflammation and fibrosis in angiotensin type1 a receptor deficient mice. J Hepatol 2005;43:317-323.
20. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005;42:987-1000.
21. Shiuchi T, Iwai M, LI HS et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertensbn 2004;43:1003-1110.
22. Ran J, Hirano T, Adachi M. Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol Endocrinol Metab 2004;287:227-232.
23. Oron-Herman M, Sela BA, Rosenthal T. Risk reduction therapy for syndrome X: comparison of several treatments. Am J Hypertens 2005; 18:372-378.
24. Kanno K, Tazuma S, Nishioka T, Hyogo H, Chayama, K. Angiotensin II participates In hepatic inflammation and fibrosis through MCP-1 expression. Dig Dis Sci 2005:50:942-948.
25. Suzuki Y, Ruiz-Ortega M, Egido J. Angiotensin II: a double-edged sword in inflammation. J Nephrol 2000;13(Suppl 3):S101-S110.
26. Li Z, Yang S, Lin H et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003:37:343-350.
27. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006;131:934-945.
28. Klover PJ, Clementi AH, Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 2005;146:3417-3427.
29. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003;52:2784-2789.
30. Jin X, Zimmers TA, Perez EA et al. Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. Hepatology 2006;43:474-484.
31. Koteish A, Diehl AM. Animals models of steatohepatltis. Besf Pract Res Clin Gastroenterol 2002;16:679-690.
32. Yoshiji H, Kuriyama S, Yoshii J et al.. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatobgy 2001;34:745-750.
33. Wolf G, Hamann A, Han DC et al. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int 1999;56:860-872.
34. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002;35:762-771.
35. Ikejima K, Okumura K, Lang T et al. The role of leptin In progression of non-alcoholic fatty liver disease. Hepatol Res 2005;33:151-154.
36. Sakaida I, Jinhua S, Uchida K, Terai S, Okita K. Leptin receptor-deficient Zucker (fa/fa) rat retards the development of pig serum-induced liver fibrosis with Kupffer cell dysfunction. Life Sci 2003;73:2491-2501.